Recruiting studies: Borderline Resectable Pancreatic Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for
Phase 2 · 1 location(s) · Ningbo Medical Center Lihuili Hospital · NCT07542002 Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Phase 1/Phase 2 · 4 location(s) · Amsterdam UMC, location VUmc · NCT06384560 The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreati
NA · 1 location(s) · Peking Union Medical College Hospital · NCT05802394 Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NA · 3 location(s) · Varian, a Siemens Healthineers Company · NCT05764720 PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017 A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07671339 Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
Phase 3 · 1 location(s) · Sahlgrenska University Hospital · NCT06714604 Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Ri
Phase 3 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07436741 Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690 Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Phase N/A · 1 location(s) · Emory University · NCT06595160 Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NA · 1 location(s) · British Columbia Cancer Agency · NCT06574620 A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06944106 Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Phase 2 · 10 location(s) · Erasme University Hospital · NCT05083247 A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
Phase N/A · 5 location(s) · Oslo University Hospital · NCT06944587 Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Phase 1 · 2 location(s) · Washington University School of Medicine · NCT06141031 Stereotactic Magnetic Resonance Guided Radiation Therapy
NA · 2 location(s) · Dana-Farber Cancer Institute · NCT04115254 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Phase 2 · 4 location(s) · Proton Collaborative Group · NCT02598349 Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06435260 HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation
Phase 2 · 2 location(s) · Zhejiang University · NCT07240766 CEB-01 in Locally Resectable Pancreatic Cancer
Phase 2 · 4 location(s) · CEBIOTEX · NCT06538857 PULSAR in Systemic Therapy for Pancreatic Cancer
Phase 2 · 1 location(s) · Samsung Medical Center · NCT07269626 Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancre
NA · 8 location(s) · University Hospital, Ghent · NCT05298722 Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable
Phase 2 · 1 location(s) · Emory University · NCT06423326 Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
Phase 1/Phase 2 · 6 location(s) · CivaTech Oncology · NCT02843945 A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
Phase N/A · 2 location(s) · Ruijin Hospital · NCT07080021 Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
NA · 2 location(s) · EBG MedAustron GmbH · NCT04894643 Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
Phase N/A · 1 location(s) · Fujian Medical University Union Hospital · NCT06310902 Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
Phase N/A · 1 location(s) · Umeå University · NCT05356039 Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · Susan E. Bates · NCT05241249 DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
NA · 2 location(s) · Ohio State University · NCT06173310

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.